Pharmacokinetics of Jinlingzi San and its single medicines in rats by LC-MS/MS.
10.19540/j.cnki.cjcmm.20241107.201
- Author:
Nan HU
1
;
Yan-Bin MENG
1
;
Si-Yu SHAN
1
;
Shuang-Shuang ZHENG
1
;
Ying-Han WANG
1
;
Lan WANG
2
;
Yu-Ling LIU
1
Author Information
1. Hebei Provincial Key Laboratory of Traditional Chinese Medicine Research and Development, Hebei Province Research Office of Traditional Chinese Medicine Against Dementia, Institute of Traditional Chinese Medicine, Chengde Medical University Chengde 067000, China.
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Jinlingzi San;
liquid chromatographymass spectrometry/mass spectrometry;
pharmacokinetics;
tetrahydropalmatine A;
tetrahydropalmatine B;
toosendanin
- MeSH:
Animals;
Rats;
Tandem Mass Spectrometry/methods*;
Drugs, Chinese Herbal/administration & dosage*;
Male;
Rats, Sprague-Dawley;
Chromatography, Liquid/methods*;
Berberine Alkaloids/blood*;
Liquid Chromatography-Mass Spectrometry
- From:
China Journal of Chinese Materia Medica
2025;50(5):1385-1391
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to investigate the scientificity and efficacy of the compatibility of Jinlingzi San from pharmacokinetics. Liquid chromatography-tandem mass spectrometry(LC-MS/MS) was utilized to determine the plasma concentrations of the active components: toosendanin, tetrahydropalmatine A, and tetrahydropalmatine B at various time points following the gavage of Jinlingzi San and its single medicines in rats. Subsequently, WinNonlin was employed to calculate pertinent pharmacokinetic parameters. The pharmacokinetic parameters in rat plasma were compared between the single medicines and the compound formula of Jinlingzi San. It was discovered that the area under the curve(AUC_(all)) and peak concentrations(C_(max)) of tetrahydropalmatine A, and tetrahydropalmatine B were significantly elevated in the compound formula group compared with the single medicine groups. Conversely, the AUC_(all )and C_(max) of toosendanin notably decreased. Furthermore, the compound formula group had longer mean residence time(MRT) and lower apparent clearance(CL/F) of all three active ingredients than the single medicine groups(P<0.05). These findings indicated that Jinlingzi San enhanced the absorption of tetrahydropalmatine A and tetrahydropalmatine B in vivo, facilitating their pharmacological actions. Concurrently, it inhibited the absorption of toosendanin, thereby preventing potential toxic reactions. Moreover, the compatibility prolonged the residence time of the active ingredients in the body. This study provides a reference for exploring the compatibility rationality of Jinlingzi San.
